The U.S. Companion Animal Health Market: An Innovation Map for Founders and Investors

Therapeutics remain science- and capital-intensive

New animal drugs can create strong defensibility, but development requires an approval strategy, manufacturing plan, safety and effectiveness evidence, and substantial time. FDA’s Center for Veterinary Medicine is central to the U.S. pathway for new animal drugs.

The opportunity is not limited to blockbuster indications. Specialty oncology, pain, dermatology, chronic disease and conditions with limited existing options can support focused development strategies, while FDA programs also address minor uses and minor species.

Diagnostics sit close to the clinical decision

Reference laboratories, point-of-care tests, imaging, pathology and molecular diagnostics can influence treatment quickly. Adoption depends on accuracy, turnaround time, sample logistics, instrument workflow and how results change a decision.

Investors should distinguish between analytical novelty and clinical utility. A technically impressive biomarker has limited commercial value if it does not answer a question veterinarians regularly face.

Software and data can scale faster—but churn matters

Practice software, communications, AI-assisted tools, pharmacy workflows and remote monitoring can reach customers faster than therapeutics, but switching costs and crowded vendor stacks create a different challenge.

Recurring revenue is attractive only when retention is healthy. The best diligence goes beyond annual recurring revenue to implementation time, support burden, gross retention, usage by role and the degree of integration into daily workflow.

Care delivery is where technology meets labor

Corporate groups, independent practices, urgent care, specialty centers, mobile clinics and telehealth models all face labor constraints. Products that extend team capacity may have value even without changing the medical standard of care.

The strongest companies understand which part of the veterinary value chain they serve and do not describe the entire animal-health economy as their total addressable market.